National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
BMC Med. 2022 Feb 8;20(1):52. doi: 10.1186/s12916-022-02262-y.
The evolution of SARS-CoV-2 has led to the emergence of several new variants, and few data are available on the impact of vaccination on SARS-CoV-2 variants. We aimed to assess the association between natural (previous infection) and induced (partial or complete vaccination) exposure to SARS-CoV-2 and the onset of new infection supported by the delta variant, and of comparing it with that supported by alpha.
We performed a test-negative case-control study, by linking population-based registries of confirmed diagnoses of infection with SARS-CoV-2, vaccinations against Covid-19 and healthcare utilization databases of the Italian Lombardy Region. Four hundred ninety-six persons who between 27 December 2020 and 16 July 2021 had an infection by the delta variant were 1:1 matched with citizens affected by alphavariant and 1:10 matched with persons who had a negative molecular test, according to gender, age and date of molecular ascertainment. We used a conditional logistic regression for estimating relative risk reduction of either variants associated with natural and/or induced immunization and corresponding 95% confidence interval (CI).
Previous infection was associated with 91% (95% CI 85% to 95%) reduced relative risk of reinfection, without evidence of significant differences between delta and alpha cases (p=0.547). Significant lower vaccinal protection against delta than alpha variant infection was observed with reduced relative risk associated with partial vaccination respectively of 29% (7% to 45%), and 62% (48% to 71%) (p=0.001), and with complete vaccination respectively of 75% (66% to 82%) and 90% (85% to 94%) (p=0.003).
Lower protection towards infections caused by the delta variant with respect to alpha variant was noticed, even after the completion of the vaccination cycle. This finding would support efforts to maximize both vaccine uptake with two doses and fulfilment with individual protection measures, especially as the delta variant is rampant worldwide presently.
SARS-CoV-2 的进化导致了几种新变体的出现,关于疫苗接种对 SARS-CoV-2 变体的影响的数据很少。我们旨在评估自然(既往感染)和诱导(部分或完全接种)暴露于 SARS-CoV-2 与 delta 变体支持的新感染发作之间的关联,并将其与 alpha 变体支持的感染发作进行比较。
我们通过将意大利伦巴第地区基于人群的 SARS-CoV-2 感染确诊诊断、Covid-19 疫苗接种和医疗保健利用数据库进行链接,开展了一项病例对照研究。2020 年 12 月 27 日至 2021 年 7 月 16 日期间,496 名感染 delta 变体的患者按照性别、年龄和分子检测日期,与感染 alpha 变体的患者 1:1 匹配,与分子检测阴性的患者 1:10 匹配。我们使用条件逻辑回归来估计自然和/或诱导免疫与任何变体相关的相对风险降低,并计算相应的 95%置信区间(CI)。
既往感染与再感染的相对风险降低 91%(95%CI 85%至 95%)相关,delta 病例和 alpha 病例之间无显著差异(p=0.547)。与 alpha 变体感染相比,delta 变体感染的疫苗保护作用明显降低,部分接种疫苗的相对风险分别为 29%(7%至 45%)和 62%(48%至 71%)(p=0.001),完全接种疫苗的相对风险分别为 75%(66%至 82%)和 90%(85%至 94%)(p=0.003)。
即使在完成疫苗接种周期后,delta 变体引起的感染的保护作用也明显低于 alpha 变体。这一发现将支持努力,最大限度地提高两剂疫苗的接种率和个人保护措施的实施,特别是因为 delta 变体目前在全球范围内肆虐。